Probable Interaction Between Warfarin and Torsemide
- 18 November 2008
- journal article
- case report
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 42 (12), 1893-1898
- https://doi.org/10.1345/aph.1l306
Abstract
Objective: To report a case in which the anticoagulation effect of warfarin appeared to be potentiated by torsemide, possibly due to an interference of metabolism through competition for the CYP2C9 isoenzyme and protein-binding displacement of warfarin. Case Summary: A 43-year-old Hispanic female with congestive heart failure, hypothyroidism, anemia, atrial fibrillation, and a mitral mechanical valve replacement was effectively anticoagulated with a target international normalized ratio (INR) of 2.5–3.5 on a warfarin regimen of 50–52.5 mg/wk. One week following the initiation of torsemide 40 mg in the morning and 20 mg in the afternoon, a marked increase in the INR occurred (6.2), requiring a warfarin dosage reduction. Subsequent titrations over a 3-week period eventually resulted in the achievement of a therapeutic INR (from 3.3 to 2.9) with a new warfarin regimen of 47.5 mg/wk. Discussion: Both torsemide and warfarin are highly protein-bound to albumin and are major substrates for the CYP2C9 isoenzyme. Competition by multiple drugs for metabolism via CYP2C9 may decrease the clearance of the drugs from systemic circulation. Addition of a drug with high protein binding may result in the displacement of other drugs that circulate highly protein-bound. Therefore, it is possible that the addition of torsemide may potentiate the anticoagulant effect of warfarin by (1) competition for metabolism through CYP2C9, with a decrease in the clearance of warfarin, and (2) protein-binding displacement of warfarin from albumin, transiently potentiating anticoagulant activity. An objective causality assessment revealed that the interaction was probable. Cardiology records confirmed the absence of fluid and heart failure status changes; therefore, these were ruled out as potential etiologies. No levothyroxine dosage changes occurred over the previous 14 months; thus, this also was ruled out as a possible etiology. Conclusions: To our knowledge, an interaction between warfarin and torsemide has not been previously reported. While further research should be done to confirm this interaction, practitioners should be made aware of its possibility.Keywords
This publication has 19 references indexed in Scilit:
- Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2008
- Drug interactions with warfarin: what clinicians need to knowCMAJ : Canadian Medical Association Journal, 2007
- Does heart failure exacerbation increase response to warfarin?A critical review of the literatureCurrent Medical Research and Opinion, 2006
- Response to Warfarin and Other Oral AnticoagulantsSouthern Medical Journal, 2000
- What is the True Clinical Significance of Plasma Protein Binding Displacement Interactions?Drug Safety, 1995
- Protein Binding Displacement Interactions and their Clinical ImportanceDrugs, 1983
- The Effect of Bumetanide on the Serum Disappearance of Warfarin SodiumThe Journal of Clinical Pharmacology, 1981
- The Effect of Furosemide and Bumetanide on Warfarin Metabolism and Anticoagulant ResponseThe Journal of Clinical Pharmacology, 1978
- Lack of a clinically important interaction between warfarin and ascorbic acidToxicology and Applied Pharmacology, 1975
- IMPACT OF ASPIRIN AND CHLORTHALIDONE ON THE PHARMACODYNAMICS OF ORAL ANTICOAGULANT DRUGS IN MAN*Annals of the New York Academy of Sciences, 1971